|Bid||6.60 x 1800|
|Ask||7.00 x 1400|
|Day's Range||6.53 - 6.96|
|52 Week Range||5.47 - 12.79|
|Beta (5Y Monthly)||2.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 14, 2023 - Nov 20, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.92|
Subscribe to Yahoo Finance Plus to view Fair Value for CVAC
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.
Regional Court Düsseldorf postpones infringement ruling on four intellectual property rights in lawsuit filed by CureVac against BioNTechRuling on infringement to be provided latest once the validity of the intellectual property rights in suit has ...
A German court on Thursday suspended a patent trial against BioNTech over the use of mRNA technology in the COVID-19 vaccine developed by the German company together with its U.S. partner Pfizer. The Duesseldorf regional court said it needed further clarification and suspended the case, brought by BioNTech competitor CureVac, pending decisions by the German and the European patent offices on a legal challenge filed by BioNTech. A separate patent infringement case brought by CureVac was previously suspended by the Duesseldorf court because a higher court first needs to review that patent's validity.